Immix Biopharma Plunges 14.11% Amid Earnings Concerns

On May 26, 2025, Immix Biopharma's stock experienced a significant drop of 14.11% in pre-market trading.

Immix Biopharma is expected to see earnings growth in the coming year, with projections moving from a loss of $0.87 to $0.85 per share. This shift in earnings expectations could be influencing investor sentiment and contributing to the recent stock price volatility.

The company's current forward price-to-sales (PS) ratio is 0.00, which is considered fair compared to its five-year average. This valuation metric suggests that the stock may not be overvalued, but the recent drop in stock price could be a result of broader market concerns or specific company developments.